Literature DB >> 29945197

A Case Study Involving U-47700, Diclazepam and Flubromazepam-Application of Retrospective Analysis of HRMS Data.

Emma Partridge1,2, Stephen Trobbiani1, Peter Stockham1,2, Cheryl Charlwood1, Chris Kostakis1.   

Abstract

The number of new psychoactive substances (NPS) available is constantly increasing, making it difficult for toxicology laboratories to keep screening methods up to date. Full scan high-resolution mass spectrometry (HRMS) is a versatile technique which allows for progressive updating of spectral databases to increase the scope of screening. It also allows for retrospective screening of data-specifically, reprocessing of data files using an updated spectral database without the need for re-extraction or reanalysis.The coronial case reported here illustrates the application of retrospective processing of HRMS data in the detection of emerging NPS. A 28-year-old male with a history of illicit drug use was found deceased at home. Initial routine screening of the post-mortem peripheral blood identified only methylamphetamine, amphetamine and trace amounts of lorazepam. A compound with an accurate mass and isotope ratio consistent with the opioid AH-7921 was also detected in the liquid chromatography (LC)-HRMS screen; however; the retention time and mass spectrum did not match the library. Further investigation confirmed the compound to be U-47700, another opioid and structural isomer of AH-7921. Several months later, after additional NPS had been added to the in-house HRMS database, retrospective screening of the HRMS data was performed, revealing the presence of designer benzodiazepines, diclazepam and flubromazepam as well as the psychedelic drug 2,5-dimethoxy-4-chloroamphetamine (DOC). Quantitative analysis gave the following results in peripheral post-mortem blood: U-47700 (330 μg/L), diclazepam (70 μg/L), flubromazepam (10 μg/L), methylamphetamine (290 μg/L) and amphetamine (150 μg/L) (DOC not quantitated). These substances, along with lorazepam and etizolam, were also confirmed in the post-mortem urine and an investigation into blood and urinary metabolites was carried out. All analyses were performed using the same LC-quadrupole-time of flight method. The cause of death was aspiration (of gastric content into airways and lungs) due to mixed drug toxicity.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29945197     DOI: 10.1093/jat/bky039

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  11 in total

Review 1.  Interpol review of toxicology 2016-2019.

Authors:  Wing-Sum Chan; George Fai Wong; Chi-Wai Hung; Yau-Nga Wong; Kit-Mai Fung; Wai-Kit Lee; Kwok-Leung Dao; Chung-Wing Leung; Kam-Moon Lo; Wing-Man Lee; Bobbie Kwok-Keung Cheung
Journal:  Forensic Sci Int       Date:  2020-05-23       Impact factor: 2.395

2.  Application of the fentanyl analog screening kit toward the identification of emerging synthetic opioids in human plasma and urine by LC-QTOF.

Authors:  Logan C Krajewski; Kenneth D Swanson; William A Bragg; Rebecca L Shaner; Craig Seymour; Melissa D Carter; Elizabeth I Hamelin; Rudolph C Johnson
Journal:  Toxicol Lett       Date:  2019-12-05       Impact factor: 4.372

Review 3.  Blood concentrations of new synthetic opioids.

Authors:  Piotr Adamowicz; Karolina Nowak
Journal:  Int J Legal Med       Date:  2021-10-22       Impact factor: 2.686

4.  The designer benzodiazepine, flubromazepam, induces reward-enhancing and cardiotoxic effects in rodents.

Authors:  Eunchong Hong; Sun Mi Gu; Jin Mook Kim; Kyung Sik Yoon; Jin-Moo Lee; Young-Hoon Kim; Soo Kyung Suh; Dohyun Lee; Heejong Eom; Jaesuk Yun; Hye Jin Cha
Journal:  Toxicol Res (Camb)       Date:  2022-07-08       Impact factor: 2.680

Review 5.  Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017-2020: A Review.

Authors:  Amanda L A Mohr; Barry K Logan; Melissa F Fogarty; Alex J Krotulski; Donna M Papsun; Sherri L Kacinko; Marilyn A Huestis; Jeri D Ropero-Miller
Journal:  J Anal Toxicol       Date:  2022-07-14       Impact factor: 3.220

6.  A New Strategy for Efficient Retrospective Data Analyses for Designer Benzodiazepines in Large LC-HRMS Datasets.

Authors:  Meiru Pan; Brian Schou Rasmussen; Petur Weihe Dalsgaard; Christian Brinch Mollerup; Marie Katrine Klose Nielsen; Michael Nedahl; Kristian Linnet; Marie Mardal
Journal:  Front Chem       Date:  2022-05-19       Impact factor: 5.545

7.  Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats.

Authors:  Michael T Truver; Christina R Smith; Nancy Garibay; Theresa A Kopajtic; Madeleine J Swortwood; Michael H Baumann
Journal:  Neuropharmacology       Date:  2020-06-10       Impact factor: 5.250

Review 8.  New psychoactive substances: a review and updates.

Authors:  Abu Shafi; Alex J Berry; Harry Sumnall; David M Wood; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2020-12-17

Review 9.  Designer Benzodiazepines: A Review of Toxicology and Public Health Risks.

Authors:  Pietro Brunetti; Raffaele Giorgetti; Adriano Tagliabracci; Marilyn A Huestis; Francesco Paolo Busardò
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-11

Review 10.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.